Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 60

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Colorectal cancer metastatic

Recruiting

Study comparing oxaliplatin and irinotecan chemotherapy effectiveness using tumor testing in patients with metastatic colorectal cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:St. Olavs Hospital HF

Non-small cell lung cancer

Recruiting

Study of JNJ-90301900 with Chemoradiation and Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:HAFNIUM OXIDE
  • Sponsor:Johnson & Johnson Enterprise Innovation Inc.

Colorectal cancer metastatic

Recruiting

Study on Regorafenib with Cyclophosphamide, Capecitabine, and Aspirin for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Regional Universitaire

Acute myeloid leukaemia refractory+1

Recruiting

Study on the Safety and Effectiveness of Eltanexor for Patients with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ELTANEXOR
  • Sponsor:Azienda Ospedaliero Universitaria Delle Marche

Breast cancer

Recruiting

Study on Low-Dose Gadolinium for Breast Cancer MRI in Patients Using Gadoteric Acid

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Gadoteric Acid
  • Sponsor:Stichting Radboud University Medical Center

Glioma

Recruiting

Study on Bevacizumab and Dexamethasone for Treating Brain Radiation Damage in Patients with High-Grade Glioma or Brain Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Acute lymphocytic leukaemia

Recruiting

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients 55+ with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Cardiff University

Non-small cell lung cancer

Recruiting

Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mps-102
  • Sponsor:Fondazione Ricerca Traslazionale

Bladder transitional cell carcinoma

Recruiting

Study on the Effectiveness and Safety of Mitomycin C with Electric Current for Treating Non-Muscle Invasive Bladder Cancer in Patients, Compared to Standard Immunotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Presurgy S.L.

Systemic mastocytosis

Recruiting

Study on Dupilumab and Fexofenadine for Treating Indolent Systemic Mastocytosis with Skin Involvement in Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Gdansk

Central nervous system neoplasm+2

Recruiting

Study of Gadobutrol for MRI in Adults with Cerebrospinal Fluid Disorders, Including Hydrocephalus and Brain Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Oslo University Hospital HF

Metastatic malignant melanoma

Recruiting

Study of TIL therapy combined with peginterferon alfa-2a and nivolumab for patients with metastatic melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:TIL CELLS
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.